80 related articles for article (PubMed ID: 25896603)
21. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
22. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
23. Determination of CUDC-101 in rat plasma by liquid chromatography mass spectrometry and its application to a pharmacokinetic study.
Zhang Q; Wen C; Xiang Z; Ma J; Wang X
J Pharm Biomed Anal; 2014 Mar; 90():134-8. PubMed ID: 24366214
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
25. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.
Zhou C; Ji J; Shi M; Yang L; Yu Y; Liu B; Zhu Z; Zhang J
Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623
[TBL] [Abstract][Full Text] [Related]
26. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
Cantarini MV; McFarquhar T; Smith RP; Bailey C; Marshall AL
Clin Ther; 2004 Oct; 26(10):1630-6. PubMed ID: 15598479
[TBL] [Abstract][Full Text] [Related]
27. LC-MS/MS method for determination of epothilone B in rat plasma and its application in pharmacokinetic study.
Lu HM; Ye M
Arzneimittelforschung; 2012 Dec; 62(12):609-13. PubMed ID: 23093482
[TBL] [Abstract][Full Text] [Related]
28. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.
Marks PA; Breslow R
Nat Biotechnol; 2007 Jan; 25(1):84-90. PubMed ID: 17211407
[TBL] [Abstract][Full Text] [Related]
29. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
[TBL] [Abstract][Full Text] [Related]
30. Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species.
Sandhu P; Andrews PA; Baker MP; Koeplinger KA; Soli ED; Miller T; Baillie TA
Drug Metab Lett; 2007 Apr; 1(2):153-61. PubMed ID: 19356036
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous determination of caffeic acid derivatives by UPLC-MS/MS in rat plasma and its application in pharmacokinetic study after oral administration of Flos Lonicerae-Fructus Forsythiae herb combination.
Zhou W; Shan J; Wang S; Ju W; Meng M; Cai B; Di L
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Feb; 949-950():7-15. PubMed ID: 24441018
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors trichostatin A and suberoylanilide hydroxamic acid attenuate ventilator-induced lung injury.
Chen HY; Li L; Fu ZJ
Pharmazie; 2014 Jan; 69(1):55-9. PubMed ID: 24601225
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacokinetics behavior of raltitrexed in rats after single injected with astragali radix].
Xing R; Zhou K; Song JW
Zhongguo Zhong Yao Za Zhi; 2013 Jun; 38(11):1823-6. PubMed ID: 24010304
[TBL] [Abstract][Full Text] [Related]
34. Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhibitor.
Wise LD; Spence S; Saldutti LP; Kerr JS
Birth Defects Res B Dev Reprod Toxicol; 2008 Feb; 83(1):19-26. PubMed ID: 18092367
[TBL] [Abstract][Full Text] [Related]
35. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
[TBL] [Abstract][Full Text] [Related]
36. Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS).
Bai F; Freeman BB; Fraga CH; Fouladi M; Stewart CF
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):169-75. PubMed ID: 16364699
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice.
Otaegui D; Rodríguez-Gascón A; Zubia A; Cossío FP; Pedraz JL
Cancer Chemother Pharmacol; 2009 Jun; 64(1):153-9. PubMed ID: 19002463
[TBL] [Abstract][Full Text] [Related]
38. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
O'Connor OA; Heaney ML; Schwartz L; Richardson S; Willim R; MacGregor-Cortelli B; Curly T; Moskowitz C; Portlock C; Horwitz S; Zelenetz AD; Frankel S; Richon V; Marks P; Kelly WK
J Clin Oncol; 2006 Jan; 24(1):166-73. PubMed ID: 16330674
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of a high-performance liquid chromatography ultraviolet method for lapatinib quantification in human plasma.
Escudero-Ortiz V; Pérez-Ruixo JJ; Valenzuela B
Ther Drug Monit; 2013 Dec; 35(6):796-802. PubMed ID: 23942544
[TBL] [Abstract][Full Text] [Related]
40. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
